Quest Partners LLC Purchases Shares of 19,801 Enhabit, Inc. (NYSE:EHAB)

Quest Partners LLC acquired a new position in Enhabit, Inc. (NYSE:EHAB) during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund acquired 19,801 shares of the company’s stock, valued at approximately $177,000.

Several other large investors have also made changes to their positions in the business. UBS Group AG grew its holdings in Enhabit by 2.0% in the 4th quarter. UBS Group AG now owns 1,666,362 shares of the company’s stock valued at $17,247,000 after buying an additional 32,611 shares during the last quarter. Paradice Investment Management LLC grew its stake in shares of Enhabit by 0.7% in the second quarter. Paradice Investment Management LLC now owns 1,525,037 shares of the company’s stock worth $13,603,000 after acquiring an additional 11,128 shares during the last quarter. Charles Schwab Investment Management Inc. increased its position in Enhabit by 25.1% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 966,515 shares of the company’s stock worth $10,003,000 after acquiring an additional 193,675 shares during the period. Orchard Capital Management LLC raised its stake in Enhabit by 5.6% during the 4th quarter. Orchard Capital Management LLC now owns 600,350 shares of the company’s stock valued at $6,214,000 after purchasing an additional 31,929 shares during the last quarter. Finally, Alberta Investment Management Corp boosted its holdings in Enhabit by 56.8% in the 4th quarter. Alberta Investment Management Corp now owns 489,532 shares of the company’s stock valued at $5,067,000 after purchasing an additional 177,360 shares during the period.

Wall Street Analyst Weigh In

Separately, Bank of America cut their price objective on shares of Enhabit from $9.00 to $8.00 and set an “underperform” rating for the company in a research report on Thursday, June 27th. One equities research analyst has rated the stock with a sell rating and six have issued a hold rating to the company. According to MarketBeat, the company has an average rating of “Hold” and an average target price of $9.35.

Insider Transactions at Enhabit

In related news, Director Jeffrey Bolton purchased 5,000 shares of the firm’s stock in a transaction that occurred on Thursday, August 22nd. The shares were acquired at an average price of $8.01 per share, with a total value of $40,050.00. Following the purchase, the director now directly owns 78,877 shares in the company, valued at $631,804.77. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 1.90% of the stock is currently owned by insiders.

Enhabit Trading Up 3.3 %

Shares of Enhabit stock opened at $8.10 on Monday. Enhabit, Inc. has a 52-week low of $7.12 and a 52-week high of $12.99. The firm has a market capitalization of $406.26 million, a PE ratio of -4.88 and a beta of 1.82. The company has a debt-to-equity ratio of 0.73, a current ratio of 1.48 and a quick ratio of 1.48. The company’s fifty day moving average price is $8.84 and its two-hundred day moving average price is $9.39.

Enhabit (NYSE:EHAB) last posted its earnings results on Tuesday, August 6th. The company reported $0.07 earnings per share for the quarter, beating analysts’ consensus estimates of $0.05 by $0.02. The business had revenue of $260.60 million for the quarter, compared to analysts’ expectations of $265.99 million. Enhabit had a negative net margin of 0.84% and a positive return on equity of 1.61%. During the same quarter in the previous year, the firm posted $0.04 earnings per share. On average, analysts expect that Enhabit, Inc. will post 0.26 EPS for the current year.

Enhabit Company Profile

Enhabit, Inc provides home health and hospice services in the United States. Its home health services include patient education, pain management, wound care and dressing changes, cardiac rehabilitation, infusion therapy, pharmaceutical administration, and skilled observation and assessment services; practices to treat chronic diseases and conditions, including diabetes, hypertension, arthritis, Alzheimer's disease, low vision, spinal stenosis, Parkinson's disease, osteoporosis, complex wound care and chronic pain, along with disease-specific plans for patients with diabetes, congestive heart failure, post-orthopedic surgery, or injury and respiratory diseases; and physical, occupational and speech therapists provide therapy services.